CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 701–800 of 1,000
Farooq, M., & Jorde, U. P. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000424 · Cited by 6
Metabolites and Genes behind Cardiac Metabolic Remodeling in Mice with Type 1 Diabetes Mellitus
Kambis, T. N., Shahshahan, H. R., & Mishra, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031392 · Cited by 5
SGLT2 Inhibitors Protect Cardiomyocytes From Myocardial Infarction: A Direct mechanism?
Zhang, J., Zhang, F., & Ge, J. (2022) · Future Cardiology · doi:10.2217/fca-2022-0058 · Cited by 6
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
Brain Regulation of Cardiac Function during Hypoglycemia
Chambers, M. E., Nuibe, E. H., & Reno, C. M. (2023) · Metabolites · doi:10.3390/metabo13101089 · Cited by 7
“While there is evidence of this association with improved heart failure outcomes [113], there is limited/no evidence of how SGLT2 inhibitors might reduce arrhythmias during hypoglycemia.”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
The role of sodium glucose co-transporter inhibitors in heart failure prevention
Garla, V. V., Subauste, A. R., Butler, J., & Lien, L. F. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107811 · Cited by 5
Case of sodium–glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis
Yeoh, H. L., Lee, M., Pan, W. J., & Ong, H. Y. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-235953 · Cited by 6
Zhou, Z., Zheng, M., Zuo, Z., & Wu, T. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14726 · Cited by 5
“60 SGLT2i also mediates a reduction in plasma uric acid level, which is associated with cardiovascular complications.”
BackgroundEmpa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
Alzaid, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0033 · Cited by 5
Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Yanai, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.22 · Cited by 5
Editorial: Heart Failure in Type 2 Diabetes – The “Forgotten” Complication
Guja, C., & Miulescu, R. D. (2018) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2018-0014 · Cited by 5
“Finally, SGLT2i are associated with a moderate rise in plasma ketones, including betahydroxybutyrate, hypothesized to be a sort of “super-fuel” that can be taken up by the heart and used very efficiently [36].”
BackgroundLandgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0459-7 · Cited by 5
“Eine Reihe von Metaanalysen umfangreicher retrospektiver Studien zu Sulfonylharnstoffen mit und ohne Metformin zeigt signifikante Steigerungen kardiovaskulärer Komplikationen und eine erhöhte Mortalität, während andere Metaanalysen einen neutralen Effekt zeigen.”
BackgroundInfluentialKuhadiya, N. D., & Mahmood, I. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4022 · Cited by 4
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
Masuda, T., Kariro, K., & Morishita, Y. (2026) · Hypertension Research · doi:10.1038/s41440-025-02516-1 · Cited by 5
Lysine β-hydroxybutyrylation: A metabolic-epigenetic interface in health and disease
Chen, C., (127892), X. C., Lyu, X., Yao, L., Ge, S., Yu, M., & Sang, R. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158410 · Cited by 6
Schubert, A., Buchholt, A. T., Khoury, A. C. E., Kamal, A., & Taieb, V. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1310091 · Cited by 5
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 7
Wodschow, H. Z., Davidovski, F. S., Christensen, J., Lassen, M. C. H., Skaarup, K. G., Nygaard, H. H., Møller, N., Rungby, J., Biering‐Sørensen, T., Rossing, P. R., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1131192 · Cited by 4
Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling
Fan, L., Meng, C., Wang, X., Wang, Y., Li, Y., Lv, S., & Zhang, J. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100263 · Cited by 4
“It is generally accepted that KBs are more ef fi cient superfuels than other substrates [35].”
BackgroundO’Brolchain, A., Maletsky, J., Mian, I., & Edwards, S. (2024) · Journal of Diabetes Research · doi:10.1155/2024/1849522 · Cited by 5
“SGLT2i are known to cause persistent but mild ketosis [16].”
BackgroundZhang, A., Kalil, R. K., Marzec, A., Coulter, S., Virani, S. S., Patel, K. V., & Segar, M. W. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8375 · Cited by 5
“26 This “fuel shift” hypothesis proposes that by reducing glucose as a metabolic substrate, SGLT2 inhibitors may induce an adaptive response, leading to increased lipid and ke-tone oxidation.”
BackgroundKolesnyk, M. Y., & Maistrovych, Y. Y. (2024) · Modern medical technology · doi:10.14739/mmt.2024.1.296545 · Cited by 4
Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
Васильевна, Л. М. (2024) · Consilium Medicum · doi:10.26442/20751753.2024.4.202763 · Cited by 5
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
Darwish, D., Kumar, P., Urs, K., & Dave, S. (2025) · Cells · doi:10.3390/cells14120919 · Cited by 6
Васильевна, Ц. О., Тимощенко, О. В., Tuzovskaia, O. V., Latyntseva, L. D., & Nikolaev, К. Y. (2022) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20220601 · Cited by 4
Jojima, T., Sakurai, S., Kishi, H., Kato, K., Iijima, T., Tomaru, T., Usui, I., & Aso, Y. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362265 · Cited by 4
Crabtree, C. D., Pan, Y., Chandrasekaran, P., Wang, Y., SCANDLING, D. M., Bedell, T., Stoner, J., Decker, D. D., Kackley, M. L., Robinson, B., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70208 · Cited by 4
“…ketones stems from sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials demonstrating mild ketosis is associated with improved outcomes in people with CVD, including a 40% reduction in cardiovascular mortality in people with type 2 diabetes (Ferrannini, Mark, & Mayoux, 2016; Taegtmeyer, 2016).”
InfluentialBatista, J. L., Makuvire, T. T., Davis, J. D., & Carbone, S. (2025) · US Cardiology Review · doi:10.15420/usc.2024.44 · Cited by 4
“56,57 T2D and HF impair the heart’s metabolic flexibility, leading to an over-reliance on non-esterified fatty acids for adenosine triphosphate generation, which results in lipotoxicity and promotes diastolic dysfunction.”
Antihyperglycemic agents and cardiovascular outcomes: recent insights
BAJAJ, H. S., Zinman, B., & Verma, S. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000435 · Cited by 6
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Chaudhary, A., Alreefi, F., & Aziz, M. (2021) · CJC Open · doi:10.1016/j.cjco.2021.01.006 · Cited by 4
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?
Faria‐Costa, G., Oliveira, J., Vilas-Boas, I., Campelo, I., Silva, E. A., Brás‐Silva, C., Silva, S. M., Antunes‐Lopes, T., & Charrua, A. (2024) · International Neurourology Journal · doi:10.5213/inj.2346250.125 · Cited by 3
“This shift leads to an increase in β-OHB, providing the heart with an alternative and advantageous fuel source, as previously described [80].”
SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_4 · Cited by 4
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dci16-0027 · Cited by 4
Self-citationSodium-Glucose Cotransporter 2 Inhibitors for Heart Failure
Yanai, H. (2017) · Journal of Endocrinology and Metabolism · doi:10.14740/jem426w · Cited by 4
Azhari, H. F., & Dawson, J. (2024) · Frontiers in Stroke · doi:10.3389/fstro.2024.1363954 · Cited by 4
Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus
Filippas-Ntekouan, S., Dimou, A. D., Dafopoulos, P., Kostara, C. E., Bairaktari, E. T., Chasapi, S. A., Spyroulias, G. A., Koufakis, T., Koutsovasilis, A., & Tsimihodimos, V. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01508-1 · Cited by 4
“Improvement of energy metabolism either locally or systemically has been proposed [6, 7].”
SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study
Yang, H., Ning, Y., Chen, M., & Jia, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309674 · Cited by 3
“43 These changes might relate to improved insulin sensitivity and glucose utilization, as amino acid metabolism has been linked to insulin resistance and T2DM pathogenesis.”
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
“SGLT2 inhibitors promote a shift in myocardial fuel utilisation towards ketone bodies (β-hydroxybutyrate), which generate more ATP per unit of oxygen than glucose or fatty acids, improving energetics in the metabolically stressed failing heart [21].”
InfluentialSilverii, G. A., Velardi, V., Marinelli, C., Lax, A., Monami, M., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71128 · Cited by 3
“On the other hand, SGLT2i could have a more specific cardiac effect, determined by a reduction of pre-and post-load and consequent decrease in oxygen consumption [18, 19], as well as by enhanced oxygen supply and a shift in substrate metabolism [20].”
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
Wang, H., Liu, X., Zhou, Q., Liu, L., Jia, Z., Qi, Y., Xu, F., & Zhang, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21952 · Cited by 3
Kugathasan, L., Ragi, N., Debnath, S., Sridhar, V. S., Maity, S., Feng, T., Treviño, E., Perkins, B. A., Cherney, D. Z. I., & Sharma, K. (2025) · Physiological Reports · doi:10.14814/phy2.70465 · Cited by 3
“This metabolic shift suggests that SGLT2 inhibition modulates mitochondrial energetics by enhancing the utilization of amino acid substrates at a systemic level (Ferrannini, Mark, & Mayoux, 2016).”
Hariyanto, T. I., Vatvani, A. D., & Yanto, T. A. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.3.326 · Cited by 3
“22 Additional mechanisms proposed include restoration of tubulo-glomerular feedback leading to reduced RAAS and sympathetic nervous system activation; osmotic diuresis resulting in decreased ventricular overload; inhibition of the sodium-hydrogen exchanger pump, thereby reducing myocardial calcium…”
Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure
Imprialos, K. P., Stavropoulos, K., & Papademetriou, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.004 · Cited by 3
Ryder, R. E. J., & DeFronzo, R. A. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.250 · Cited by 5
The revolution of the anti-diabetic drugs in cardiology
Verdecchia, P., Angeli, F., Cavallini, C., Aita, A., Turturiello, D., & Reboldi, G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa084 · Cited by 3
Bao, L., Gao, X., Xie, K., & Li, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.716083 · Cited by 4
Somaili, M., Oraibi, O., Mohrag, M., Hommadi, A., Moafa, E., Kulaybi, A., Shobayli, S., Moafa, R. H., Mhgfory, G., Jaafari, A., et al. (2022) · Cureus · doi:10.7759/cureus.24284 · Cited by 3
Association between energy intake patterns and outcome in US heart failure patients
Fang, Z., Wang, Z., Cao, X., Wang, Z., Yu, C., Ju, W., & Li, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1019797 · Cited by 4
Glycerol and β-hydroxybutyrate: friends or foes?
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad368 · Cited by 3
Singh, M. P., Agrawal, N. K., Agrawal, A., Kushwah, S. S., Krishna, E., & Singh, J. M. (2024) · Cureus · doi:10.7759/cureus.60919 · Cited by 6
“This action elevates the intraluminal electrical potential, subsequently promoting magnesium reabsorption [17].”
BackgroundНиколаевна, К. О., Korotkov, D. A., Sazhina, A. S., & Bogomolov, A. N. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3014 · Cited by 3
Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?
Ismail, Z., Aboughdir, M., Duric, B., Kaka, S., Chan, J. S. K., Bayatpoor, Y., & Harky, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408376 · Cited by 3
“SGLT2i provide an alternative myocardial energy supply in the form of ketone bodies, namely beta-hydroxybutyrate (βOHB), which enhances myocardial ener-getics [49].”
Heart Failure and Chronic Kidney Disease in Type 2 Diabetes
Cernea, S. (2016) · Journal of Interdisciplinary Medicine · doi:10.1515/jim-2016-0066 · Cited by 3
So Many Antihyperglycemics: How to Choose? A Practical Approach
CHENG, A. Y. Y. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.04.001 · Cited by 3
Krentz, A. J., & Rodriguez‐Araujo, G. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0209-3 · Cited by 3
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.09.021 · Cited by 3
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.01.001 · Cited by 3
Bauduceau, B., & Monnier, L. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30023-9 · Cited by 3
Хасанов, Н. Р. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4049 · Cited by 3
Sodium–Glucose Cotransporter 2 Inhibitors and the Kidney
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0071 · Cited by 4
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Athyros, V. G., Imprialos, K. P., Doumas, M. N., & Karagiannis, A. I. (2016) · Clinical Lipidology · doi:10.1080/17584299.2016.1230316 · Cited by 3
Borg, R., & Persson, F. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.02 · Cited by 3
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_6 · Cited by 3
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 4
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun
Simó, R., & Hernández, C. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.07.009 · Cited by 2
Simó, R., & Hernández, C. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.07.030 · Cited by 2
Tiver, K. D., Chew, D. P., Tan, J. Y., Lambrakis, K., Pasquale, C. G. D., & Ganesan, A. N. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.12.004 · Cited by 2
Demidova, T. Y., Кislyak, O. A., Геннадьевна, Л. К., & Харчилава, Л. Д. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-4-15 · Cited by 2
Lo, K. B., Iskarous, K., & Sankaranarayanan, R. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.002 · Cited by 3
Nakamura, Y., Horie, I., Yano, H., Nomoto, H., Fukui, T., Yuyama, Y., Kawamura, T., Ueda, M., Yamamoto, A., Hirota, Y., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061287 · Cited by 4
“It has been hypothesized that mild but persistent hyperketonemia during treatment with an SGLT2 inhibitor results in significant risk reductions in both cardiovascular and renal outcomes in individuals with type 2 diabetes [35].”
Zhang, A., Zhichen, B., Kidoguchi, S., Nishiyama, A., Hu, X., & Nakano, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70118 · Cited by 4
“10 – 12 In non-diabetic models, we previously showed that SGLT2 inhibition preserved the renal capillary network and attenuated ischemia – reperfusion-induced kidney injury associated with tubular polarity loss.”
Okumura, T., Bando, Y., Isobe, S., Fujita, N., Sera, F., Ikeda, Y., Yajima, A., Nagai, T., Hiraiwa, H., Morimoto, R., et al. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00260-6 · Cited by 2
“SGLT2 inhibitors increase the production of ketone bodies, which are more efficient energy substrates for the heart than fatty acids [35].”
Neshat, S., Moradi, H., Bidares, M., Heidari, A., Marvast, A. F., Ortega, R., & Heshmat, K. (2025) · Cureus · doi:10.7759/cureus.99752 · Cited by 2
“In heart failure, where myocardial metabolic flexibility is impaired, this "thrifty substrate" phenomenon allows the myocardium to utilize ketone bodies more efficiently than fatty acids, improving energy yield per unit of oxygen [9, 11].”
Chen, J., Wan, F., Wu, K., Xie, X., & WU, T. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2613138 · Cited by 2
“SGlt2i promote ketone body production and utilisation, thereby improving cardiac energy metabolism (Ferrannini et al. 2016; Saucedo-Orozco et al. 2022). β-HB, a lipid-derived ketone body, is elevated by SGlt2i through increased levels of serum free fatty acids and β-HB (wallenius et al. 2022).”
Sato, T., Isagawa, T., Sugiura, Y., Sawaki, D., Nakagama, Y., Kuchimaru, T., Minatsuki, S., Sato, S., Ono, K., Chuluun-Erdene, A., et al. (2026) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2026.01.008 · Cited by 2
“Ketone body oxidation was increased in patients treated with an SGLT2 inhibitor, 17,18,27 and is thought to serve as an adaptive response harboring potential benefit.”
Kümet, Ö., Polat, F., Durmaz, O., Can, V., Kaya, A., Ayhan, G., & Özbek, E. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113147 · Cited by 2
More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases
Vecchio, L. D., Fernández‐Fernández, B., Fornoni, A., Kronbichler, A., & Ortiz, A. (2026) · Drugs · doi:10.1007/s40265-026-02286-1 · Cited by 2
Kong, Y., Peng, X., Fan, W., Zhang, L., Wu, Y., Zheng, M., & Shan, C. (2026) · Biochemical Journal · doi:10.1042/bcj20240504 · Cited by 2
Habas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Ziegler, D., Kempler, P., Bala, C. G., Mankovsky, B., Schnell, O., Spallone, V., Stirban, A. O., & Tesfaye, S. H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02241-w · Cited by 2
“This high glucagon-to-insulin ratio acts as a powerful fasting signal to adipose tissue, accelerating lipolysis and elevating circulating free fatty acids (FFAs) and tri-glycerides (TGs) [44, 45].”
Kwon, H. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.4.225 · Cited by 3
“이 밖에도 최근에는 SGLT2 억제제 투여 후 케톤체의 혈중 농도가 증가하는데 산혈증까지 발생할 정도로 심각한 상황이 아니라면 심장과 신장에 포도당 혹은 지방산보다 훨 씬 에너지효율 측면에서 우월한 연료 원으로 사용될 수 있 어서 심장, 신 보호효과가 나타났다는 주장도 있다[14,15].”
Integrating cardioprotective glucose-lowering medications into clinical practice
Mudaliar, S. R. (2017) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000142 · Cited by 2
Cardiovascular outcome trials in type 2 diabetes: A critical analysis
Ashraf, H., & Ahmad, J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.001 · Cited by 3
Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
Paramasivan, A. M., Purushothaman, A., & Desouza, C. V. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1106-1 · Cited by 2
Possibilities of cardio- and nephroprotective eff ects of drugs of the SGLT2 inhibitor group
Константинович, К. В., Borovkova, N. Y., Kurashina, V. A., & Bakka, T. E. (2021) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2021-99-3-172-176 · Cited by 2
Kehinde, S. A., Ore, A., Olajide, A. T., & Fatokun, T. P. (2023) · Food Chemistry Advances · doi:10.1016/j.focha.2023.100227 · Cited by 2
Pharmacological Treatment of Ischemic Heart Disease
Giannoni, A., Gentile, F., & Borrelli, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25879-4_19 · Cited by 2
Effects of Hypoxia and Reoxygenation on Metabolic Profiles of Cardiomyocytes
Condori, L. D. M., Vivas, C. V., Barreto, Y. B., Gomes, L. F., Alencar, A. M., & Bloise, A. C. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01249-1 · Cited by 3
“On the other hand, Ferrannini et al. [35] show that the oxidation of ketones bodies is comparable to glucose and pyruvate in terms of oxygen ef fi ciency, which makes it an equally ef fi cient fuel under metabolically stressed conditions.”
Baloch, A. A., Shabir, K. U., Kiran, Z., Fatima, N., & Hasan, S. M. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01380-y · Cited by 2
“Lastly, it has been hypothesized by different studies that this increased plasma ketone concentration [24–26] worked as a readily oxidizable fuel for the myocardium [27, 28] and provided the beneficial cardiovascular effects in type 2 diabetes mellitus patients [29].”
Ferrannini, E., Baldi, S., Scozzaro, T., Ferrannini, G., & Hansen, M. K. (2024) · JCI Insight · doi:10.1172/jci.insight.180637 · Cited by 3
“The increased supply of energy-rich substrates arguably translates into protection of high-energy output organs — such as the heart and the kidney — on the way to failure (10, 11).”
Self-citationBiological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“According to the EMPA-REG OUTCOME trial, SGLT-2 inhibitors increase the production of ketone bodies, which support the mitochondria of cardiomyocytes, and potentiate ATP production, leading to an increase in cardiac contractility [138].”
Alsarkhi, L. N., Eda, S., Abdul, R. H. M., Hussaini, H., Fadeyi, O. A., Chaudhari, S. S., Rauf, M. A., & Allahwala, D. (2025) · Cureus · doi:10.7759/cureus.90205 · Cited by 5
“Additionally, empagliflozin improves insulin sensitivity, which is central to NAFLD pathogenesis, by reducing glucotoxicity and enhancing peripheral glucose utilization [21].”
Mangkuliguna, G., HANDISURYA, I. W. A., Jahja, F. E., & Adrianto, N. (2025) · Annals of Pediatric Cardiology · doi:10.4103/apc.apc_158_25 · Cited by 2
“[15] The anti-inflammatory and antifibrotic properties of SGLT2i further contribute to their efficacy by reducing myocardial fibrosis and adverse cardiac remodeling.”
Naing, S., Poliyedath, A., Khandelwal, S., & Sigala, T. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1245093 · Cited by 3
SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajput, R., & Ved, J. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.031 · Cited by 2
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.